Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 45 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 10478435

    Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  2. US 10472357

    Triazolopyridine compounds and methods for the treatment of cystic fibrosis

    Flatley Discovery Lab, LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  3. US 10471144

    Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  4. US 10471061

    Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  5. US 10471051

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  6. US 10465004

    Frizzled receptor antibodies for treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  7. US 10464994

    Recombinant clusterin and use thereof in the treatment and prevention of disease

    The Board of Regents of the University of Texas System · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  8. US 10464967

    Non-hormonal steroid modulators of NF-κβ for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  9. US 10463655

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  10. US 10457670

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted

  11. US 10456439

    NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

    ACADEMISCH MEDISCH CENTRUM · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted

  12. US 10457676

    Capsazepine analogs for the treatment of cancer and other proliferative diseases

    The Board of Regents of the University of Texas System · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted

  13. US 10449191

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  14. US 10449171

    Compositions and methods for diagnosis and treatment of metabolic syndrome

    The United States of America, as represented by Secretary of the Navy · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  15. US 10450364

    Hyperimmunized egg product for treatment of necrotic enteritis in poultry

    United States of America as represented by the Secretary of the Air Force · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  16. US 10449176

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  17. US 10449170

    Compositions for diagnosis and treatment of type 2 diabetes

    The United States of America, as represented by Secretary of the Navy · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  18. US 10442852

    Methods and compositions for treatment of symptoms associated with intracranial hemorrhage

    The Board of Regents of the University of Texas System · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  19. US 10441580

    Iloperidone for the treatment of schizophrenia

    VANDA PHARMACEUTICALS INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  20. US 10441614

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Krystal Biotech, Inc. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  21. US 10434078

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  22. US 10434134

    Peptide treatment for inflammation and fibrosis

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  23. US 10435428

    Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

    Theravance Biopharma R&D IP, LLC · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  24. US 10428057

    Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.